MRNA Moderna, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
MRNA Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$41.83
Analyst Target
$36.75
-12.1%
Downside
52W High
$45.4
52W Low
$22.28
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe deterioration in fundamental performance. Despite strong short-term price momentum (+37.1% in 1M), the company is unprofitable across all margins—gross, operating, and net—with negative earnings growth of -1800% YoY. Valuation metrics are distorted by negative earnings (Forward P/E of -6.02) and an elevated Price/Sales ratio of 7.32, while insiders have shown bearish sentiment via recent selling activity. Although the balance sheet shows low leverage and high liquidity, persistent losses and collapsing revenue (-45.4% YoY) overshadow these strengths, placing the stock at high fundamental risk.
Key Strengths
Strong liquidity position with Current Ratio of 3.92 and Quick Ratio of 3.51
Low Debt/Equity ratio of 0.08, indicating minimal leverage risk
Recent quarterly earnings surprises have been positive, beating estimates in 3 of last 4 quarters
Significant short-term price momentum: +37.1% in 1 month and +23.9% in 1 year
Cash-rich balance sheet with substantial total cash (exact figure unavailable but implied by liquidity ratios)
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and deteriorating fundamentals
Deeply unprofitable: Profit Margin of -139.61%, Operating Margin of -25.59%, and Gross Margin of -107.62%
Revenue declining sharply at -45.4% YoY, indicating demand or commercialization issues
Negative Forward P/E (-6.02) and lack of meaningful profitability suggest valuation is not grounded in earnings
Insider selling activity in the last 6 months signals lack of confidence from corporate insiders
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare MRNA against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning MRNA from our newsroom.
Newest → oldest
No matching news yet.